Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This research is being done to try to reduce radiation side effects that happen with the
standard radiation methods. Generally surgery, radiation therapy, and sometimes chemotherapy
are standard treatment for people with squamous cell carcinoma of the oropharynx.
The study will look at giving a slightly smaller dose of radiation (de-intensification) to
see if regularly expected late toxicities (two years after receiving treatment) can be
reduced. This study will also try to see if the smaller dose of radiation is equally
effective at treating the cancer and to see if it improves quality of life. Along with this
radiation treatment plan some participants in this study will have surgery on their tumor and
or receive chemotherapy (cisplatin or carboplatin). The possible surgery and or chemotherapy
will be up to the participant's doctor.
Study participants will be tested for the Human Papillomavirus (HPV). This tissue test is
required for this study. Some studies have suggested that HPV-related cancer is biologically
and clinically different as compared to non-HPV-related cancer. Some studies have found that
patients with HPV-related oropharynx cancer have a better response to treatment. This test
will help researchers learn more about HPV-related cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins